Efficacy and Acceptability of Tadenan®(Pygeum africanum Extract) in the Treatment of Benign Prostatic Hyperplasia (BPH): A Multicentre Trial in Central Europe

References

• Abrams P., Schulman C. C., Vaage S., the European Tamsulosin Study Group. Tamsulosin, a selective αic.-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic ‘obstruction’ (symptomatic BPH). Br. J. Urol. 1995; 76: 325–3361. Abrams P., Schulman C. C., Vaage S., the European Tamsulosin Study Group. Tamsulosin, a selective αic.-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic ‘obstruction’ (symptomatic BPH). Br. J. Urol. 1995; 76: 325–336
   PubMedGoogle Scholar
• Andro M. C., Riffaud J. P. Pygeum afrkanum extract for the treatment of patients with benign prostatic hyperplasia: a review of 25 years of published experience. Curr. Ther. Res. 1995; 56: 796–8172. Andro M. C., Riffaud J. P. Pygeum afrkanum extract for the treatment of patients with benign prostatic hyperplasia: a review of 25 years of published experience. Curr. Ther. Res. 1995; 56: 796–817
   Web of Science ®Google Scholar
• Armitage P., Berry G. Statistical Methods in Medical Research. Blackwells, Oxford 1987; 104–106; 410–4113. Armitage P., Berry G. Statistical Methods in Medical Research. Blackwells, Oxford 1987; 104–106; 410–411
   Google Scholar
• Barlet A., Albrecht J., Aubert A., et al. Efficacy of Pygeum afrkanum extract in the treatment of micturitional disorders due to benign prostatic hyperplasia. Evaluation of objective and subjective parameters. Wien Klin. Wochenschr. 1990; 102: 667–6734. Barlet A., Albrecht J., Aubert A., et al. Efficacy of Pygeum afrkanum extract in the treatment of micturitional disorders due to benign prostatic hyperplasia. Evaluation of objective and subjective parameters. Wien Klin. Wochenschr. 1990; 102: 667–673
   PubMed Web of Science ®Google Scholar
• Barry N. J., Fowler F. J., O'Leary M. P., et al. The American Urological Association symptom index for benign prostatic hyperplasia. J. Urol. 1992; 148: 1549–15575. Barry N. J., Fowler F. J., O'Leary M. P., et al. The American Urological Association symptom index for benign prostatic hyperplasia. J. Urol. 1992; 148: 1549–1557
   PubMed Web of Science ®Google Scholar
• Berry S. J., Coffey D. S., Walsh P. C., et al. The development of human benign prostatic hyperplasia with age. J. Urol. 1984; 132: 474–4796. Berry S. J., Coffey D. S., Walsh P. C., et al. The development of human benign prostatic hyperplasia with age. J. Urol. 1984; 132: 474–479
   PubMed Web of Science ®Google Scholar
• Byrnes C. A., Morton A. S., Liss C. L., et al. Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hypertrophy: a community based study. Clin. Therap. 1995; 17: 956–9697. Byrnes C. A., Morton A. S., Liss C. L., et al. Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hypertrophy: a community based study. Clin. Therap. 1995; 17: 956–969
   PubMed Web of Science ®Google Scholar
• Cussenot O., Villette J. M., Valeri A., et al. Plasma neuroendocrine markers in patients with benign prostatic-hyperplasia and prostatic cancer. J. Urol. 1996; 155: 1340–13438. Cussenot O., Villette J. M., Valeri A., et al. Plasma neuroendocrine markers in patients with benign prostatic-hyperplasia and prostatic cancer. J. Urol. 1996; 155: 1340–1343
   PubMed Web of Science ®Google Scholar
• Doremieux J., Masson J. C., Bollack C. Adenome de prostate. Effets cliniques et modifications histologiques apportes par un complexe lipido-sterolique extrait de, Pygeum afrkanum. J. Med. Strasbourg 1973; 4: 253–2579. Doremieux J., Masson J. C., Bollack C. Adenome de prostate. Effets cliniques et modifications histologiques apportes par un complexe lipido-sterolique extrait de, Pygeum afrkanum. J. Med. Strasbourg 1973; 4: 253–257
   Google Scholar
• Dufour B., Choquenet C., Reveol M., et al. Etude controlee des effets de l'extrait de Pygeum afrkanum sur les symptomes fonctionnels de 1′adenome proslatique. Ann. Urol 1984; 18: 193–19510. Dufour B., Choquenet C., Reveol M., et al. Etude controlee des effets de l'extrait de Pygeum afrkanum sur les symptomes fonctionnels de 1′adenome proslatique. Ann. Urol 1984; 18: 193–195
   PubMedGoogle Scholar
• Hansen B. J., Meyhoff H. H., Nordling J., et al. Placebo effects in the pharmacological treatment of uncomplicated benign prostatic hyperplasia. Scan. J. Urol. Nephrol 1996; 30: 373–37711. Hansen B. J., Meyhoff H. H., Nordling J., et al. Placebo effects in the pharmacological treatment of uncomplicated benign prostatic hyperplasia. Scan. J. Urol. Nephrol 1996; 30: 373–377
   PubMed Web of Science ®Google Scholar
• Janknegt R. A., Chappie C. R., for the doxazosin study groups. Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of five studies. Eur. Urol 1993; 24: 319–32612. Janknegt R. A., Chappie C. R., for the doxazosin study groups. Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of five studies. Eur. Urol 1993; 24: 319–326
   PubMed Web of Science ®Google Scholar
• Jardin A., et al, the BPH-ALF Group. Alfuzosin lor treatment of benign prostatic hypertrophy. Lancet 1991; 337: 1457–146113. Jardin A., et al, the BPH-ALF Group. Alfuzosin lor treatment of benign prostatic hypertrophy. Lancet 1991; 337: 1457–1461
   PubMed Web of Science ®Google Scholar
• Jonler M., Riehmann M., Bruskewitz R. C. Benign prostatic hyperplasia. Current pharmacological treatment. Drugs 1994; 47: 66–8114. Jonler M., Riehmann M., Bruskewitz R. C. Benign prostatic hyperplasia. Current pharmacological treatment. Drugs 1994; 47: 66–81
   PubMed Web of Science ®Google Scholar
• Mebust W. K., Bosch R., Donovan J., et al. Symptom evaluation, quality of life and sexuality. Proceedings of the Second International Consultation on Benign Prostatic Hyperplasia (BPH), A. T. K. Cockett, S. Khoury, Y. Aso. Scientific Communication International, Jersey 1993; 153–20915. Mebust W. K., Bosch R., Donovan J., et al. Symptom evaluation, quality of life and sexuality. Proceedings of the Second International Consultation on Benign Prostatic Hyperplasia (BPH), A. T. K. Cockett, S. Khoury, Y. Aso. Scientific Communication International, Jersey 1993; 153–209
   Google Scholar
• Ramos F. M., Abraham D. A. The effect of Pygeum afrkanum on symptomatic benign prostatic hyperplasia. Philip. J. Urol 1993; 3: 35–3816. Ramos F. M., Abraham D. A. The effect of Pygeum afrkanum on symptomatic benign prostatic hyperplasia. Philip. J. Urol 1993; 3: 35–38
   Google Scholar
• Stober P. W., Seth A. K. Multiple comparisons: When and how?. Drug Inf. J. 1993; 27: 651–66117. Stober P. W., Seth A. K. Multiple comparisons: When and how?. Drug Inf. J. 1993; 27: 651–661
   Google Scholar
• Stoner E. Three-year safely and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 1994; 43: 284–29418. Stoner E. Three-year safely and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 1994; 43: 284–294
   PubMed Web of Science ®Google Scholar
• Yablonsky E., Nicolas V., Riffaud J. P., et al. Antiproliferative effect of Pygeum afrkanum extract on rat prostatic fibroblasts. J. Urol 1997; 157: 2381–238719. Yablonsky E., Nicolas V., Riffaud J. P., et al. Antiproliferative effect of Pygeum afrkanum extract on rat prostatic fibroblasts. J. Urol 1997; 157: 2381–2387
   PubMed Web of Science ®Google Scholar